BTIG analysts maintained their Buy rating on Zimmer Biomet (NYSE:ZBH) with a price target of $126.00 after the company ...

Zimmer Biomet Holdings, Inc. ZBH is scheduled to report fourth-quarter 2024 results on Feb. 6, before market open. See the ...

(Reuters) - Medical device maker Zimmer Biomet Holdings forecast full-year ... due to strong demand for its devices used in hip and knee procedures. Combined sales at Zimmer's hips and knees ...

When shares of Zimmer ... Biomet by Zimmer, the deal was set to create an $8 billion giant in the musculoskeletal industry, with investors hoping to benefit from synergies between knees, hip ...

With the $1.1 billion acquisition, Zimmer Biomet expects its sports medicine, extremities and trauma segment will outpace ...

Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the ...

Zimmer Biomet (NYSE: ZBH) shares dipped slightly today on fourth-quarter results that came in just ahead of the consensus ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price ...

Zimmer Biomet also recently received US regulatory approval of its Oxford partial cementless knee. While Oxford has been a dominant competitor in the partial knee category, the cementless version ...

Zimmer Biomet Holdings, Inc. ZBH is scheduled to report fourth-quarter 2024 results on Feb. 6, before market open. See the Zacks Earnings Calendar to stay ahead of market-making news. In the last ...